Listed Companies' Analysis | Ranking | Industry Ratios | Ratios (IBRX) | Financials (IBRX)

ImmunityBio, Inc. (IBRX) Financial Analysis and Rating

Comparison Analysis Based on SEC Data

Year:

20252026

Financial Position and Performance

Annual | Quarterly

Compare with a competitor

Financial Ratios Benchmarking

Year:

20252026

Additional Ratios (not used in score calculation)

Auditor's Conclusion

We have performed a comparative analysis of the balance sheet and income statement of ImmunityBio, Inc. (hereafter – the "Company") for Q1 2025 as filed with the U.S. Securities and Exchange Commission (SEC). The primary business activity of the Company is "Biological Products, Except Diagnostic Substances" (SIC code 2836). In our analysis, we compared the key financial ratios of the Company with the average (median) values of those ratios calculated for the Company's specific industry sector and for all companies. The averages were calculated using data from Q1 2025 financial statements filed with the SEC through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). By comparing each of the eleven key metrics to the median, we have reached an overall conclusion about the quality of the Company's financial condition. All calculations and conclusions were performed using software and methodologies developed by ReadyRatios.

Based on our analysis of the Company's key financial ratios, we have determined the following. The financial condition of ImmunityBio, Inc. in 2025 is worse than the typical financial condition of companies in the "Biological Products, Except Diagnostic Substances" industry.

A comparison of the Company's financial ratios with the average ratios for all industries leads to the same conclusion. The financial position of ImmunityBio, Inc. is worse than that of most listed companies that file financial statements with the U.S. Securities and Exchange Commission.

Financial Position and Performance History

More on ImmunityBio, Inc.

Closest Competitors

See all industry leaders

Financial Data Source and Analysis Principles

The above is a comparative analysis of the company's financial position and performance. The comparison is based on official financial statements filed with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR) (about 10,000 largest publicly traded companies). The comparison is made using the eleven key financial ratios (see the table above). The company's financial ratios are compared with the median of the ratios for all companies and for companies in the same industry, as well as to the quartiles of these ratios. Each ratio value is assigned a score between -2 and +2 depending on its position relative to the quartiles (-2 – below the first quartile; -1 – between the first and the second quartile; +1 – between the second and the third quartile; +2 – above the third quartile; 0 – the ratio value deviates from the median by no more than 5% of the difference between the median and the quartile closest to the ratio value). To draw a conclusion from the analysis, the individual scores are weighted equally to produce an overall score ranging from -2 and +2.

	much better (+1 - +2incl)
	better (from 0.11 to +1incl)
	about the same (from -0.11incl to +0.11incl)
	worse (from -1incl to -0.11)
	much worse (from -2incl to -1)

"Change during the year" calculation

Please note that this analysis does not indicate that the company's financial position is good or bad, but rather describes it in comparison to other U.S. businesses. For a detailed financial analysis, please use "ReadyRatios Financial Analysis" - load the data into the program>>